Journal article
Donor Diabetes and 1-Year Descemet Membrane Endothelial Keratoplasty Success Rate: A Randomized Clinical Trial
JAMA ophthalmology, Vol.143(12), pp.1043-1051
12/01/2025
DOI: 10.1001/jamaophthalmol.2025.4253
PMCID: PMC12534858
PMID: 41105094
Abstract
Importance If the success of Descemet membrane endothelial keratoplasty (DMEK) is not affected by whether the donor has diabetes, then the donor pool should expand.
Objective To determine whether the 1-year DMEK success rate is affected by the presence of diabetes in the donor.
Design, Setting, and Participants This was a multicenter, double-masked, randomized clinical trial conducted from February 2022 to July 2025 at 28 clinical sites (46 surgeons), with donor corneas provided by 13 eye banks in the US. Included in the study were individuals undergoing low to moderate risk DMEK (95% for Fuchs endothelial corneal dystrophy). Study data were analyzed from April to September 2025.
Intervention DMEK performed with a cornea from a donor without or with diabetes, assigned using a minimization procedure (comparable with randomization) to achieve an approximate 2:1 distribution, respectively.
Main Outcomes and Measures Graft success at 1 year
Results A total of 1097 individuals (1421 study eyes; median [IQR] age, 71 [66-76] years; 631 female [57.5%]) were included in the study. The 1-year cumulative probability of graft success was 96.3% (95% CI, 95.0%-97.5%) among 912 study eyes (64.2%) receiving tissue from donors without diabetes and 97.1% (95% CI, 95.5%-98.4%) among 509 study eyes (35.8%) receiving tissue from donors with diabetes (difference between groups = 0.7 percentage points; 95% CI, −1.2 to 2.6; P = .63). The 1-year cumulative probability of graft success was 96.5% (95% CI, 93.6%-98.9%) in the mild donor diabetes severity subgroup (n = 173) and 97.3% (95% CI, 95.4%-98.8%) in the moderate to severe donor diabetes severity subgroup (n = 336), using a diabetes severity rating scale based on medical history. The rates of primary donor failure, early failure related to surgical complications, and subsequent failure were as follows: 2.5% (23 of 912), 0.7% (6 of 912), and 0.3% (3 of 912), respectively, in recipients of tissue from a donor without diabetes, and 2.6% (13 of 509), 0.4% (2 of 509), and 0%, respectively, among recipients of tissue from a donor with diabetes. There were no failures due to graft rejection.
Conclusions and Relevance The 1-year success rate in eyes undergoing DMEK with successfully prepared tissue was very high regardless of donor diabetes status. These results, supported by the separately reported finding that endothelial cell loss and cornea morphometry after 1 year were not affected by donor diabetes status, provide strong support for having no restrictions on the use of tissue from donors with diabetes for DMEK.
Trial Registration ClinicalTrials.gov Identifier: NCT05134480
Details
- Title: Subtitle
- Donor Diabetes and 1-Year Descemet Membrane Endothelial Keratoplasty Success Rate: A Randomized Clinical Trial
- Creators
- Francis W Price Jr - Price Vision GroupLoretta B Szczotka-Flynn - Case Western Reserve UniversityMarianne O Price - Cornea Research Foundation of AmericaColleen E Bauza - Jaeb Center for Health ResearchZachariah W Reed - Jaeb Center for Health ResearchBaha M Arafah - University Hospitals of ClevelandMark A Greiner - University of IowaPaula J Johnson - Verdier Eye Center, Grand Rapids, MichiganDevon B Keeler - Verdier Eye Center, Grand Rapids, MichiganShahzad I Mian - University of MichiganSanjay V Patel - Mayo ClinicSudeep Pramanik - Chicago Cornea Consultants (United States)Mark C Soper - Lions Eye Bank (Coralville)Mark A Terry - Legacy HealthMichael S Titus - Eversight, Ann Arbor, MichiganDavid D Verdier - Verdier Eye Center, Grand Rapids, MichiganCraig Kollman - Jaeb Center for Health ResearchRoy W Beck - Jaeb Center for Health ResearchJonathan H Lass - Case Western Reserve UniversityDiabetes Endothelial Keratoplasty Study Group
- Resource Type
- Journal article
- Publication Details
- JAMA ophthalmology, Vol.143(12), pp.1043-1051
- DOI
- 10.1001/jamaophthalmol.2025.4253
- PMID
- 41105094
- PMCID
- PMC12534858
- NLM abbreviation
- JAMA Ophthalmol
- ISSN
- 2168-6165
- eISSN
- 2168-6173
- Publisher
- American Medical Association; CHICAGO
- Grant note
- Gift of SightCleveland Eye Bank FoundationSan Antonio Eye BankDepartment of Health and Human ServicesSan Diego Eye BankVisionFirstNational Institutes of HealthUtah Lions Eye BankThe Cornea SocietyKenneth Maverick MDCorneaGenIowa Lions Eye BankBeauty of SightNational Eye InstituteVisionGiftEye Bank Association of AmericaEye Bank for Sight RestorationEye Bank of KentuckyLions Eye Bank of WisconsinEversight
This work was supported by cooperative agreements with the National Eye InstituteNational Institutes of HealthDepartment of Health and Human ServicesEye Bank Association of AmericaThe Cornea SocietyCleveland Eye Bank FoundationBeauty of SightCorneaGenEversightEye Bank for Sight RestorationEye Bank of KentuckyGift of SightIowa Lions Eye BankKenneth Maverick MDLions Eye Bank of WisconsinSan Antonio Eye BankSan Diego Eye BankUtah Lions Eye BankVisionFirstVisionGift, , (EY030030 5 and EY030039). Sponsors: , , , (formerly Florida Lions Eye Bank), , , , , , , , , , , , , and .
- Language
- English
- Electronic publication date
- 10/17/2025
- Date published
- 12/01/2025
- Academic Unit
- Pharmaceutical Sciences and Experimental Therapeutics; Ophthalmology and Visual Sciences
- Record Identifier
- 9985016009802771
Metrics
9 Record Views